Strategies for the use of Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors in cancer therapy

Abstract

Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control. There is potentially a large patient population that may also benefit from PARP inhibitor treatment, either in monotherapy or in combination with chemotherapy. Here, we describe the multifaceted role of PARP inhibitors and discuss which treatment options could potentially be useful to gain disease control without potentiating side effects. © 2011 by the authors; licensee MDPI, Basel, Switzerland.